GlassScriptPhysician profile
Dirk M Collevecchio
NPI 1467931360
$6,787.67
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,248 · 2022: $2,489 · 2023: $50.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,092.97 | 2021-2023 | |
| Viiv Healthcare Company | $1,023.16 | 2021-2022 | |
| Gilead Sciences, INC. | $876.18 | 2021-2023 | |
| Emd Serono, INC. | $335.04 | 2021-2022 | |
| Novo Nordisk INC | $322.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $280.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $270.41 | 2021-2022 | |
| Janssen Biotech, INC. | $216.92 | 2021-2022 | |
| Bausch Health US, LLC | $215.45 | 2021-2022 | |
| Janssen Products, LP | $199.90 | 2021-2022 | |
| Theratechnologies INC. | $175.41 | 2021-2022 | |
| Amarin Pharma, INC. | $167.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $136.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.16 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $119.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $113.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.29 | 2021-2022 | |
| Lilly USA, LLC | $100.92 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $66.37 | 2021 | |
| Antares Pharma, INC. | $65.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $64.05 | 2021 | |
| Collegium Pharmaceutical, INC. | $63.93 | 2021 | |
| Adlon Therapeutics L.P. | $56.91 | 2021 | |
| Glaxosmithkline, LLC. | $56.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.58 | 2022 | |
| Amgen INC. | $45.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $45.22 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $32.13 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.79 | 2021 | |
| Apria Healthcare LLC | $21.53 | 2021 | |
| Clarus Therapeutics INC. | $19.76 | 2021 | |
| Medtronic, INC. | $17.43 | 2021 | |
| Napo Pharmaceuticals INC | $17.15 | 2021 | |
| Biodelivery Sciences International, INC. | $15.98 | 2021 | |
| Janssen Scientific Affairs, LLC | $10.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dirk Collevecchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.